{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:32:36Z","timestamp":1789749156824,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biologicals.2026.101886","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:08:11Z","timestamp":1778296091000},"page":"101886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence \u2013 a meeting report"],"prefix":"10.1016","volume":"95","author":[{"given":"Laurence","family":"de Moerlooze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bartalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alane","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector S.","family":"Izurieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3682-3255","authenticated-orcid":false,"given":"Randee","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Nealon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-0360","authenticated-orcid":false,"given":"Lidia","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto A.","family":"Palmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-6728","authenticated-orcid":false,"given":"Robert C.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3079","authenticated-orcid":false,"given":"Dean K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-231X","authenticated-orcid":false,"given":"Suely","family":"Tuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vandendriessche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-551X","authenticated-orcid":false,"given":"Marc","family":"Baay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8961-8564","authenticated-orcid":false,"given":"Danielle","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Neels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaatje","family":"Bollaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2026.101886_bib1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/pds.5123","article-title":"Randomized, observational, interventional, and real-world-what's in a name?","volume":"29","author":"Concato","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.biologicals.2026.101886_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2024.101750","article-title":"The role of real-world evidence for regulatory and public health decision-making for accelerated Vaccine Deployment- a meeting report","volume":"85","author":"Bollaerts","year":"2024","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2026.101886_bib3","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1056\/NEJMp2202669","article-title":"Delivering pandemic vaccines in 100 days \u2014 what will it take?","volume":"387","author":"Saville","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA Animal rule","volume":"1","author":"Beasley","year":"2016","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.biologicals.2026.101886_bib5","series-title":"Correlates of vaccine-induced protection: methods and implications","year":"2013"},{"key":"10.1016\/j.biologicals.2026.101886_bib6","series-title":"EMA workshop: non-clinical data for regulatory decision-making on the efficacy of medical countermeasures","year":"2025"},{"key":"10.1016\/j.biologicals.2026.101886_bib7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJMoa2412439","article-title":"Tecovirimat for clade I MPXV infection in the Democratic Republic of Congo","volume":"392","author":"Ali","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib8","series-title":"NIH","article-title":"Tecovirimat is safe but ineffective as treatment for clade II mpox","year":"2025"},{"key":"10.1016\/j.biologicals.2026.101886_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2037350","article-title":"Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches","volume":"18","author":"Absalon","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.biologicals.2026.101886_bib10","series-title":"WHO preferred product characteristics for group B streptococcus vaccines","year":"2017"},{"key":"10.1016\/j.biologicals.2026.101886_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127131","article-title":"Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries","volume":"58","author":"Le Doare","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib12","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.vaccine.2019.04.039","article-title":"The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib13","series-title":"Key criteria for the ethical acceptability of controlled human infection studies during public health emergencies","year":"2025"},{"key":"10.1016\/j.biologicals.2026.101886_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018594","article-title":"Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model","volume":"7","author":"de Graaf","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.biologicals.2026.101886_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/ciz840","article-title":"Controlled human infection with Bordetella pertussis induces asymptomatic, immunizing colonization","volume":"71","author":"de Graaf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163121","article-title":"Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge","volume":"133","author":"Diks","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.biologicals.2026.101886_bib17","first-page":"155","article-title":"Controlled human infection with Bordetella pertussis","volume":"445","author":"de Graaf","year":"2024","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.biologicals.2026.101886_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101313","article-title":"Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study","author":"de Graaf","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.biologicals.2026.101886_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101211","article-title":"Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis","volume":"6","author":"Gbesemete","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.biologicals.2026.101886_bib20","series-title":"Vaccines and related biological products advisory committee meeting","article-title":"Use of controlled human infection models to support licensure of pertussis vaccines","year":"2024"},{"key":"10.1016\/j.biologicals.2026.101886_bib21","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib23","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: spidnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib24","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biologicals.2026.101886_bib25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib27","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib28","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/infdis\/jiac455","article-title":"One- and two-dose vaccinations with modified vaccinia Ankara-Bavarian nordic induce durable B-Cell memory responses comparable to replicating smallpox vaccines","volume":"227","author":"Ilchmann","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and immunogenicity of modified vaccinia Ankara-Bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib32","article-title":"A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18-40 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2026.101886_bib33","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE\u00ae smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib34","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/OLQ.0000000000001978","article-title":"JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the vaccine adverse event reporting system and V-safe, United States, 2022 to 2023","volume":"51","author":"Duffy","year":"2024","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib36","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.15585\/mmwr.mm7149a4","article-title":"Safety monitoring of JYNNEOS vaccine during the 2022 Mpox outbreak - united States, may 22-October 21, 2022","volume":"71","author":"Duffy","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.biologicals.2026.101886_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126409","article-title":"MVA-BN vaccine effectiveness: a systematic review of real-world evidence in outbreak settings","volume":"42","author":"Mason","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib38","article-title":"Effectiveness and safety of the MVA-BN vaccine against mpox in At-Risk individuals in the United States (USMVAc)","volume":"12","author":"Back","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biologicals.2026.101886_bib39","article-title":"The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response","volume":"99","author":"Oom","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2026.101886_bib40","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1038\/s41467-024-48180-w","article-title":"Predicting vaccine effectiveness for mpox","volume":"15","author":"Berry","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.biologicals.2026.101886_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","article-title":"Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study","volume":"23","author":"Cohn","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib42","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani Shamez","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib44","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/j.vaccine.2023.05.025","article-title":"Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: a systematic review","volume":"41","author":"Cinconze","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib45","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2105\/AJPH.2015.302996","article-title":"Ethical rationale for the Ebola \"Ring Vaccination\" trial design","volume":"106","author":"Rid","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.biologicals.2026.101886_bib46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2026.101886_bib47","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib48","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","article-title":"Chikungunya fever","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.biologicals.2026.101886_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012254","article-title":"Clinical outcomes of chikungunya: a systematic literature review and meta-analysis","volume":"18","author":"Rama","year":"2024","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-025-01360-1","article-title":"Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia","volume":"11","author":"Morello","year":"2026","journal-title":"npj Vaccines"},{"key":"10.1016\/j.biologicals.2026.101886_bib52","article-title":"Chikungunya virus VLP vaccine: phase 3 trial in adolescents and adults","author":"Richardson","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.biologicals.2026.101886_bib53","article-title":"Chikungunya virus VLP vaccine: phase 3 trial in adults \u226565 years of age","author":"Tindale","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.biologicals.2026.101886_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tim.2013.12.011","article-title":"Global spread of dengue virus types: mapping the 70 year history","volume":"22","author":"Messina","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.biologicals.2026.101886_bib55","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1016\/j.vaccine.2018.05.097","article-title":"A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands","volume":"37","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cmi.2020.09.011","article-title":"Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study","volume":"27","author":"van Werkhoven","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.biologicals.2026.101886_bib57","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/cid\/ciab649","article-title":"Vaccine-preventable disease incidence based on clinically, radiologically, and etiologically confirmed outcomes: systematic literature review and Re-analysis of pneumococcal conjugate vaccine efficacy trials","volume":"74","author":"Bollaerts","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib58","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib59","article-title":"Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England","volume":"35","author":"Kirsebom","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.biologicals.2026.101886_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127870","article-title":"Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England","volume":"67","author":"Abdul Aziz","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S2213-2600(22)00354-X","article-title":"Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib62","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study","volume":"9","author":"Tartof","year":"2022","journal-title":"Lancet Reg Health, Am"},{"key":"10.1016\/j.biologicals.2026.101886_bib63","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","article-title":"Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare System","volume":"15","author":"Caffrey","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.biologicals.2026.101886_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae370","article-title":"Effectiveness of BNT162b2 XBB vaccine against XBB and JN.1 sublineages","volume":"11","author":"Tartof","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib65","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1038\/s41467-025-59344-7","article-title":"Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US veterans affairs healthcare system","volume":"16","author":"Appaneal","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.biologicals.2026.101886_bib66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.biologicals.2026.101886_bib68","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","article-title":"The disease burden of influenza beyond respiratory illness","volume":"39","author":"Macias","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib69","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/infdis\/jir171","article-title":"Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong","volume":"203","author":"Warren-Gash","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib70","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.gaceta.2011.09.033","article-title":"Influenza-related mortality in Spain, 1999-2005","volume":"26","author":"L\u00f3pez-Cuadrado","year":"2012","journal-title":"Gac Sanit"},{"key":"10.1016\/j.biologicals.2026.101886_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-7622-2-6","article-title":"Influenza associated excess mortality in Germany, 1985-2001","volume":"2","author":"Zucs","year":"2005","journal-title":"Emerg Themes Epidemiol"},{"key":"10.1016\/j.biologicals.2026.101886_bib72","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"144","author":"Fr\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.biologicals.2026.101886_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100327","article-title":"High-dose influenza vaccine in older adults by age and seasonal characteristics: systematic review and meta-analysis update","volume":"14","author":"Lee","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.biologicals.2026.101886_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-022-00444-6","article-title":"The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England","volume":"7","author":"Nealon","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.biologicals.2026.101886_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2021.03.007","article-title":"Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial","volume":"237","author":"Hollingsworth","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.biologicals.2026.101886_bib76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ahj.2025.07.069","article-title":"A pragmatic individually randomized trial to evaluate the effectiveness of high-dose vs standard-dose influenza vaccine in older adults: rationale and design of the DANFLU-2 trial","volume":"291","author":"Johansen","year":"2026","journal-title":"Am Heart J"},{"key":"10.1016\/j.biologicals.2026.101886_bib77","unstructured":"Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-S\u00e1nchez C, Loiacono MM, Harris RC, et al. High-dose vs. standard-dose influenza vaccine and cardiovascular outcomes in older adults: the FLUNITY-HD prespecified pooled analysis. Circulation.0."},{"key":"10.1016\/j.biologicals.2026.101886_bib78","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/S0140-6736(25)01742-8","article-title":"Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis","volume":"406","author":"Johansen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2026.101886_bib79","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib80","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMc2311560","article-title":"RENOIR trial - RSVpreF vaccine efficacy over two seasons","volume":"391","author":"Walsh","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib81","article-title":"Efficacy, immunogenicity, and safety of the bivalent RSV prefusion F (RSVpreF) vaccine in older adults over 2 RSV seasons","author":"Walsh","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib82","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50832","article-title":"Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease","volume":"7","author":"Tartof","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biologicals.2026.101886_bib83","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2026.101886_bib84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(24)00796-5","article-title":"Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study","volume":"25","author":"Bajema","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2026.101886_bib85","article-title":"Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75-79 years in England","author":"Symes","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.biologicals.2026.101886_bib86","article-title":"RSV prefusion F vaccine for prevention of hospitalization in older adults","author":"Lassen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2025.07.068","article-title":"A pragmatic individually randomized trial to evaluate bivalent RSV prefusion F protein-based vaccine effectiveness for preventing RSV hospitalizations in adults aged 60 years or above (DAN-RSV): rationale and trial design","volume":"291","author":"Lassen","year":"2026","journal-title":"Am Heart J"},{"key":"10.1016\/j.biologicals.2026.101886_bib88","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2025.08.023","article-title":"Effect of RSV vaccine on heart failure hospitalizations: a prespecified analysis of the DAN-RSV trial","volume":"86","author":"Skaarup","year":"2025","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.biologicals.2026.101886_bib89","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1093\/eurheartj\/ehaf679","article-title":"Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial","volume":"46","author":"Pareek","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.biologicals.2026.101886_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002754","article-title":"Risk and rates of hospitalisation in young children: a prospective study of a South African birth cohort","volume":"4","author":"Wedderburn","year":"2024","journal-title":"PLOS Glob Publ Health"},{"key":"10.1016\/j.biologicals.2026.101886_bib91","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib92","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib93","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2213-2600(14)70139-0","article-title":"Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial","volume":"2","author":"Palmu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.biologicals.2026.101886_bib94","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.vaccine.2018.02.088","article-title":"Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial","volume":"36","author":"Palmu","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2026.101886_bib95","series-title":"Guideline for good clinical practice E6(R3)","year":"2025"},{"key":"10.1016\/j.biologicals.2026.101886_bib96","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/aje\/kwaf053","article-title":"Exploring the application of target trial emulation in vaccine evaluation: scoping review","volume":"194","author":"Komura","year":"2025","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.biologicals.2026.101886_bib97","article-title":"Target trial emulation without matching: a more efficient approach for evaluating vaccine effectiveness using observational data","author":"Wu","year":"2025","journal-title":"ArXiv"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510562600014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510562600014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:08:09Z","timestamp":1787659689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104510562600014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":97,"alternative-id":["S104510562600014X"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2026.101886","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence \u2013 a meeting report","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2026.101886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}],"article-number":"101886"}}